Research programme: epilepsy and Huntington's disease therapeutics - InMed Pharmaceuticals

Drug Profile

Research programme: epilepsy and Huntington's disease therapeutics - InMed Pharmaceuticals

Latest Information Update: 28 Oct 2014

Price : $50

At a glance

  • Originator Cannabis Technologies
  • Developer InMed Pharmaceuticals
  • Class Cannabinoids
  • Mechanism of Action Gene expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Epilepsy; Huntington's disease

Most Recent Events

  • 23 Oct 2014 InMed Pharmaceuticals enters into a strategic collaboration with the researchers at the University of British Columbia to develop a drug delivery technology for its therapeutics
  • 16 Oct 2014 Cannabis Technologies is now called InMed Pharmaceuticals
  • 26 Jun 2014 Early research in Huntington's disease in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top